Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Methicillin-resistant Staphylococcus aureus community-acquired pneumonia in infa...
Journal Information
Vol. 37. Issue 8.
Pages 551-552 (October 2019)
Vol. 37. Issue 8.
Pages 551-552 (October 2019)
Scientific letter
DOI: 10.1016/j.eimce.2019.04.008
Full text access
Methicillin-resistant Staphylococcus aureus community-acquired pneumonia in infants
Neumonías adquiridas en la comunidad por Staphylococcus aureus resistente a meticilina en lactantes
Visits
...
Irene Martín Espína, David Aguilera-Alonsoa,
Corresponding author
davidaguilera1988@gmail.com

Corresponding author.
, Adela García-Pereab, Fernando Baquero-Artigaoa
a Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales, Hospital Universitario La Paz, Madrid, Spain
b Servicio de Microbiología, Hospital Universitario La Paz, Madrid, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Characteristics of infants admitted with community-acquired methicillin-resistant Staphylococcus aureus pneumonia.
Additional material (1)
Full Text

Pneumonia is a major cause of morbidity and mortality in children. Over the past 2 decades, a slight increase in the prevalence of Staphylococcus aureus as the causative agent has been observed.1 Among children hospitalised with community-acquired pneumonia (CAP), S. aureus is currently the causative agent in 1% of cases, and 15% of cases of typical CAP are of bacterial origin.2

A gradual increase in the rate of community-acquired methicillin-resistant S.aureus (MRSA) strains has also been observed in some countries.1,3 These isolates are characterised as being more virulent since Panton-Valentine leukocidin (PVL) is produced more readily,4 with MRSA pneumonia being more common in younger children, especially infants.1

A retrospective review of children under the age of 2 years hospitalised at our hospital with CA-MRSA pneumonia over the past 5 years (2013–2017) has been performed in order to describe their clinical and epidemiological characteristics.

Three cases were identified, all involving children under the age of 6 months born in Spain to immigrant families (Table 1). The 3 patients developed severe pneumonia with pleural effusion and parenchymal necrosis (X-ray images included in Appendix. Supplementary material) and clinical deterioration was observed with the usual antibiotic therapy. All isolates were susceptible in vitro to clindamycin and trimethoprim-sulfamethoxazole. After getting the culture results back (3–4 days after hospitalisation), the antibiotic regimen was changed to linezolid in 2 cases while the third patient continued to receive vancomycin. However, this had to be changed to linezolid after 72h due to no signs of clinical improvement. The outcome was favourable in all cases, with complete clinical resolution at the time of discharge.

Table 1.

Characteristics of infants admitted with community-acquired methicillin-resistant Staphylococcus aureus pneumonia.

  Case 1  Case 2  Case 3 
Age  One month  Three months  Five months 
Gender  Male  Male  Male 
Family origin/MRSA isolate from family  Paraguayan mother/MRSA nasal colonisation  Filipino mother/MRSA pneumonia  Dominican family/grandmother and brother/MRSA nasal colonisation 
Clinical manifestations  Fever without a focus  Fever, tachypnoea and grunting  Fever, grunting and difficulty breathing 
Empirical antibiotic therapy  Ampicillin and cefotaxime  Cefotaxime and vancomycin  Cefotaxime and clindamycin 
Chest X-ray  Necrotising pneumonia in the right upper lobe with pleural effusion  Necrotising pneumonia in the right lower lobe with pleural effusion  Necrotising pneumonia in the left lower lobe with pleural effusion 
Clinical deterioration  Day 4 of hospitalisation (tachypnoea and hypoventilation of the right hemithorax)  Day 3 of hospitalisation (increased pleural effusion)  Day 4 of hospitalisation (increased difficulty breathing) 
Admission to the PICU  Admission upon deterioration and need for chest drain, non-invasive ventilation required  Not required  Not required 
Microbiology  MRSA in pleural fluid  MRSA in pleural fluid  MRSA in pleural fluid 
Panton-Valentine leukocidin  Positive  Positive  Positive 
Targeted therapy  Linezolid  1. Vancomycin2. Linezolid  Linezolid 
Clinical outcome  Favourable  Favourable  Favourable 

MRSA: methicillin-resistant Staphylococcus aureus; PICU: paediatric intensive care unit.

Methicillin resistance in community-acquired S. aureus in children was first described in Spain in 2006. These strains currently account for 5–10% of all community-acquired S. aureus isolates in children.5 Most of the cases reported are skin and soft tissue infections.5

Community-acquired S. aureus pneumonia is associated with high mortality rates (1–5%)6 and a higher risk of lung necrosis and abscesses.7 In a recent European study on invasive community-acquired S. aureus infections in children, methicillin-resistant isolates produced more cases of pneumonia than methicillin-susceptible strains and infection severity was associated with PVL production.4

MRSA pneumonia often presents with unilateral consolidation, pneumatoceles and pleural effusion8 and is more common in younger infants. At our hospital we found no cases of CA-MRSA pneumonia in infants over the age of 6 months. In children over the age of 2 years, the radiological findings, need for surgery and complications of MRSA pneumonia are similar to those observed in infants.6

MRSA carrier status increases the risk of pneumonia caused by this strain up to six-fold,3 and the rate of intrafamilial spread is very high.6 MRSA colonisation in Spain is more common among the immigrant population, especially among immigrants from South America.9 There is an ongoing spirited debate regarding the need for decolonisation in children and their family members. Decolonisation seems to be well advised in children with risk factors, such as premature infants, immunosuppressed children or patients admitted to intensive care units, and their relatives.

The American Academy of Pediatrics recommends the use of vancomycin or clindamycin in suspected cases of MRSA pneumonia.10 Once advantage of clindamycin is that it is active against PVL, but experience in actual cases of pneumonia is very limited and there may be resistant isolates. Vancomycin shows poor tissue penetration and its toxicity requires the use of serial loading doses. Linezolid is an excellent alternative, since its activity against MRSA is similar to that of vancomycin and it shows adequate penetration into lung tissue and antitoxic activity. Although the use of linezolid in paediatrics is off-label, pharmacokinetic and safety studies have demonstrated that it is a well-tolerated drug, with adequate plasma concentrations at the established doses, and that it also allows sequential administration due to its excellent oral bioavailability.

To conclude, MRSA must be suspected as the causative agent in cases of CAP with radiological signs of clinical deterioration (necrosis and pleural effusion) despite conventional empirical antibiotic therapy, especially in infants born to immigrant families. Linezolid is a good alternative to vancomycin in these patients.

Appendix. Supplementary material
Supplementary data

The following are the supplementary data to this article:

References
[1]
M.A. Carrillo-Marquez, K.G. Hulten, W. Hammerman, L. Lamberth, E.O. Mason, S.L. Kaplan.
Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas children's hospital.
Pediatr Infect Dis J, 30 (2011), pp. 545-550
[2]
S. Jain, D.J. Williams, S.R. Arnold, S. Fakhran, R. Balk, A.M. Bramley, et al.
Community-acquired pneumonia requiring hospitalization among U.S. children.
N Engl J Med, 372 (2015), pp. 835-845
[3]
S. Aliberti, L.F. Reyes, P. Faverio, G. Sotgiu, S. Dore, A.H. Rodriguez, et al.
Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study.
Lancet Infect Dis, 16 (2016), pp. 1364-1376
[4]
M. Gijón, M. Bellusci, B. Petraitiene, A. Noguera-Julian, V. Zilinskaite, P. Sanchez Moreno, et al.
Factors associated with severity in invasive community-acquired Staphylococcus aureus infections in children: a prospective European multicentre study.
Clin Microbiol Infect, 22 (2016),
[5]
F. Chaves.
Emergence of paediatric infections due to community-associated methicillin-resistant Staphylococcus aureus: should we sound the alarm?.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 672-674
[6]
K.A. Len, L. Bergert, S. Patel, M. Melish, C. Kimata, G. Erdem.
Community-acquired Staphylococcus aureus pneumonia among hospitalized children in Hawaii.
Pediatr Pulmonol, 45 (2010), pp. 898-905
[7]
I.B. Masters, A.F. Isles, K. Grimwood.
Necrotizing pneumonia: an emerging problem in children?.
[8]
G. Erdem, L. Bergert, K. Len, M. Melish, K. Kon, R. DiMauro.
Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii.
Pediatr Radiol, 40 (2010), pp. 1768-1773
[9]
A. Manzur, A.M. Dominguez, M. Pujol, M.P. González, E. Limon, A. Hornero, et al.
Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain.
Clin Microbiol Infect, 14 (2008), pp. 377-380
[10]
J.S. Bradley, C.L. Byington, S.S. Shah, B. Alverson, E.R. Carter, C. Harrison, et al.
The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.
Clin Infect Dis, 53 (2011), pp. e25-e76

Please cite this article as: Martín Espín I, Aguilera-Alonso D, García-Perea A, Baquero-Artigao F. Neumonías adquiridas en la comunidad por Staphylococcus aureus resistente a meticilina en lactantes. Enferm Infecc Microbiol Clin. 2019;37:551–552.

Copyright © 2018. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
Supplemental materials
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.